Core Viewpoint - OS Therapies has successfully closed a warrant exercise inducement and exchange offer, raising $4.2 million to support its regulatory and pre-commercial efforts for its lead product, OST-HER2, aimed at treating osteosarcoma [1][2]. Financial Summary - The company raised a total of $4.2 million in gross proceeds from the offering [1]. - The funds will primarily be used for regulatory efforts and to advance strategic alternatives for its OS Animal Health subsidiary [1][2]. Product Development - OST-HER2 is the lead asset of OS Therapies, designed to treat recurrent, fully resected pulmonary metastatic osteosarcoma, and has received various designations from the FDA [3][4]. - The company plans to submit a Biologics Licensing Application (BLA) for OST-HER2 in 2025, which could yield a Priority Review Voucher (PRV) if approved [4]. - OS Therapies is also advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), utilizing proprietary technology [5]. Strategic Plans - The company aims to pursue a Biologics Licensing Authorization under the Accelerated Approval Program for OST-HER2 within the next 18 months [2]. - OS Therapies intends to evaluate strategic alternatives for its canine osteosarcoma program and report final data for its OST-504 prostate cancer study [2][3]. - The company is focused on improving the treatment landscape for metastatic osteosarcoma patients while minimizing cash expenditure [2].